RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio, RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Upneeq is a non-surgical treatment option for acquired blepharoptosis. Co.'s product candidate, arbaclofen extended release tablets, designed for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis. The RVLP average annual return since 2018 is shown above.
The Average Annual Return on the RVLP average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RVLP average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RVLP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|